BTIG analyst David Larsen downgraded P3 Health Partners to Neutral from Buy without a price target following the company’s Q4 report. The analyst cites P3’s higher than expected medical claims costs, increases in reserves, lack of visibility, and “fairly tight” cash position for the downgrade. The firm is concerned that with ongoing utilization and medical cost pressures, the company’s 2024E EBITDA guidance is at risk.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
